Premium
Ionic Basis of Pharmacological Therapy in Brugada Syndrome
Author(s) -
MÁRQUEZ MANLIO F.,
SALICA GABRIEL,
HERMOSILLO ANTONIO G.,
PASTELÍN GUSTAVO,
GÓMEZFLORES JORGE,
NAVA SANTIAGO,
CÁRDENAS MANUEL
Publication year - 2007
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1111/j.1540-8167.2006.00681.x
Subject(s) - medicine , brugada syndrome , cilostazol , mexiletine , sotalol , quinidine , pharmacotherapy , proarrhythmia , implantable cardioverter defibrillator , asymptomatic , drug , cardiology , procainamide , intensive care medicine , anti arrhythmia agents , ventricular tachycardia , atrial fibrillation , pharmacology , aspirin
An implantable cardioverter‐defibrillator is considered the only effective therapy to terminate ventricular arrhythmias in symptomatic patients with Brugada syndrome. However, it does not prevent future arrhythmic episodes. Only antiarrhythmic drug therapy can prevent them. There have been several reports of a beneficial effect of oral quinidine in both asymptomatic and symptomatic patients. Other possible beneficial oral agents could be I to blockers. Intravenous isoproterenol has been reported to be especially useful in abolishing arrhythmic storms in emergency situations. Also, isolated case reports on the usefulness of cilostazol, sotalol, and mexiletine have been described. The present article reviews the mechanisms by which these drugs may act and their possible role in the pharmacotherapy of this disease.